Searching for ideal dendritic cell for cancer vaccines

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	SKÁLOVÁ Kateřina MACKOVÁ Klára OČADLÍKOVÁ Darina HÁJEK Roman MICHÁLEK Jaroslav
Year of publication	2008
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Dendritic cells (DC) are antigen-presenting cells that are able to activate both helper and cytotoxic T-lymphocytes and induce antitumour immunity. That makes them a suitable source for in vitro cancer vaccines production. Dendritic cells for clinical application should produce high levels of interleukin-12 (IL-12), which supports antitumour response of the immune system. In this study different conditions of the DC maturation and their effect on the DC immunophenotype and IL-12 production were compared. For clinical grade DC preparations maturation with bacterial lipopolysaccharide (LPS) and interferon-gamma seems to be the most suitable combination.
Related projects:	University Research Centre - Czech Myeloma Group